Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Epistem Announces Further Partnership With The University of Manchester

Published: Tuesday, April 22, 2014
Last Updated: Tuesday, April 22, 2014
Bookmark and Share
Partnership will allow the Company to expand its existing range of wound healing models.

Epistem Holdings Plc has announced a further partnership with The University of Manchester to further the understanding of the biology of chronic delayed wound healing associated with skin ulcers.

The team, led by Dr Matthew Hardman have been awarded an MRC Industry Collaboration Agreement (MICA) grant from the UK Medical Research Council to help fund the investigations. Chronic delayed wound healing is most often found in the elderly and those with diabetes.

Due to the increasingly aged population and rising incidence of diabetes the frequency of chronic wounds is increasing. However, there are very limited treatments available. The research, which investigates the role of specific inflammatory mediators produced by macrophages, is intended to lead to new preclinical models to evaluate potential new therapies in this area, as well as generate new therapeutic opportunities.

Dr Hardman is a world-leading expert in the molecular and cellular aspects of pathological healing and heads a multi-disciplinary research group within the Manchester Healing Foundation Centre for Tissue Regeneration at the University. Epistem's Contract Research Services Division provides specialized preclinical and scientific research services to drug development and personal care companies in the areas of oncology, mucositis, inflammation (inflammatory bowel disease and rheumatoid arthritis), wound healing and skincare. Epistem are experienced in commercializing new technologies and the partnership will allow the Company to expand its existing range of wound healing models.

Dr Hardman, who is based in the University's Faculty of Life Sciences, said: "It is a real privilege to be awarded this collaborative grant sponsored by the Medical Research Council. This partnership represents a tremendous opportunity to realize the potential of our work."

Catherine Booth, Managing Director at Epistem, added: "We are delighted to be working with Dr Hardman again, who is a highly regarded wound healing expert, and to be able to provide our customers with access to cutting edge preclinical models."

Epistem will be giving two oral presentations on recent additions to its wound healing portfolio at The Symposium on Advanced Wound Care (SAWC) on Thursday 24th April.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Epistem Announces Opening of US Laboratory
Laboratory will support the expansion of Epistem's contract research division.
Thursday, March 06, 2014
Epistem Announces Evaluation of Genedrive® for Pathogen Detection
Epistem in cooperative agreement with the US Air Force and with Johns Hopkins University.
Thursday, January 16, 2014
Epistem Presents GenetRx™ Clinical Data from Two Recently Completed Studies
Data presented on the use of scalp hair to assess androgen receptor directed therapies and to identify novel pharmacodynamic markers for an antisense molecule.
Thursday, November 12, 2009
Epistem Presents Further Data Supporting its Plucked Hair Biomarker Technology
Data on the effects of Gemcitabine on epithelial tissue released at the Institute of Cancer Research Centenary Conference.
Thursday, June 11, 2009
Epistem to Present Erlotinib Biomarker Data at AACR Meeting
Epistem plc will present results from its recently completed preclinical plucked hair biomarker study.
Wednesday, April 15, 2009
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!